The search of new biomarkers in the prediction of BCG response in patients with high-risk NMIBC. - Suppr | 超能文献

The search of new biomarkers in the prediction of BCG response in patients with high-risk NMIBC.

作者信息

Martinez Rodriguez Roberto H, Amon Sesmero Jose H

机构信息

Urology Department, University Hospital Rio Hortega, Valladolid, Spain.

出版信息

World J Urol. 2021 Feb;39(2):629-630. doi: 10.1007/s00345-020-03195-y. Epub 2020 Apr 4.

DOI:10.1007/s00345-020-03195-y

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

The search of new biomarkers in the prediction of BCG response in patients with high-risk NMIBC.

World J Urol. 2021 Feb;39(2):629-630. doi: 10.1007/s00345-020-03195-y. Epub 2020 Apr 4.

2

Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.根治性肾输尿管切除术治疗上尿路上皮癌后膀胱内卡介苗治疗后续非肌层浸润性膀胱癌的结果。

BJU Int. 2018 May;121(5):764-773. doi: 10.1111/bju.14111. Epub 2018 Jan 21.

3

Editorial comment.

J Urol. 2009 Nov;182(5):2203. doi: 10.1016/j.juro.2009.07.148. Epub 2009 Sep 16.

4

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.EORTC 列线图和风险分组用于预测非肌肉浸润性 Ta-T1 期尿路上皮膀胱癌患者接受 1-3 年卡介苗维持治疗后的复发、进展、疾病特异性和总生存情况。

Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23.

5

Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study.卡介苗短缺与膀胱癌复发的相关性：一项单中心回顾性研究。

Urol Oncol. 2020 Nov;38(11):851.e11-851.e17. doi: 10.1016/j.urolonc.2020.07.014. Epub 2020 Aug 13.

6

Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.膀胱内化疗联合卡介苗治疗非肌层浸润性膀胱癌：系统评价与荟萃分析。

BJU Int. 2013 May;111(6):977-83. doi: 10.1111/j.1464-410X.2012.11390.x. Epub 2012 Dec 17.

7

Unmet Clinical Needs and Future Perspectives in Non-muscle-invasive Bladder Cancer.非肌层浸润性膀胱癌未满足的临床需求及未来展望

Eur Urol Focus. 2018 Jul;4(4):472-480. doi: 10.1016/j.euf.2018.08.010. Epub 2018 Aug 30.

8

BCG and bladder cancer.

N Z Med J. 2010 Nov 5;123(1325):8-9.

9

Intravesical ICIs to reduce toxicity in NMIBC.膀胱内免疫检查点抑制剂以降低非肌层浸润性膀胱癌的毒性。

Nat Rev Urol. 2022 Dec;19(12):694. doi: 10.1038/s41585-022-00674-2.

10

Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.BCG 免疫治疗治疗初发高级别非肌肉浸润性膀胱癌患者治疗前后 PD-L1 表达的预后意义。

World J Urol. 2020 Oct;38(10):2537-2545. doi: 10.1007/s00345-019-03065-2. Epub 2020 Jan 3.

本文引用的文献

1

Non-technical skills for urological surgeons (NoTSUS): development and evaluation of curriculum and assessment scale.泌尿外科医师非技术技能（NoTSUS）：课程和评估量表的制定和评估。

World J Urol. 2021 Jun;39(6):2231-2237. doi: 10.1007/s00345-020-03406-6. Epub 2020 Aug 18.

2

Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC.联合评估瘤周Th1/Th2极化和外周免疫作为预测高危非肌层浸润性膀胱癌患者卡介苗反应的新生物标志物。

Oncoimmunology. 2019 Apr 13;8(8):1602460. doi: 10.1080/2162402X.2019.1602460. eCollection 2019.